GYRE
Gyre Therapeutics, Inc. NASDAQ Listed Apr 12, 2006$6.15
+0.65%
vs $6.11
Mkt Cap $634.6M
52w Low $5.56
17.8% of range
52w High $8.87
50d MA $6.18
200d MA $7.28
P/E (TTM)
-77.3x
EV/EBITDA
184.5x
P/B
3.9x
Debt/Equity
0.0x
ROE
9.3%
P/FCF
-3525.3x
RSI (14)
41.60
ATR (14)
$0.28
Beta
6.40
50d MA
$6.18
200d MA
$7.28
Avg Volume
93.8K
Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. It offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under phase 3 studies for dermatomyositis and systemic sclerosis-associated interstitial lung disease, pneumoconiosis, and diabetic kidney disease. The company is also involved the development of F351 (Hydronidone), a structural derivative of ETUARY (Pirfenidone), under Phase 3 studies for the treatment of chronic hepatitis B liver fibrosis; and under Phase 1 studies for liver fibrosis associated with nonalcoholic associated steatohepatitis. In addition, its development pipeline includes F573, under Phase 2 studies for the treatment of acute/acute-on-chronic liver failure; F528, under preclinical stage for the treatment of chronic obstructive pulmonary disease; and F230, under preclinical stage for the treatment of pulmonary arterial hypertension. The company was founded in 2002 and is headquartered in San Diego, California. Gyre Therapeutics, Inc. operates as a subsidiary of GNI USA, Inc.
12770 High Bluff Drive · San Diego, CA 92130 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 7, 2026 | BMO | — | — | — | 8.04 | -1.7% | -12.1% | +5.7% | -5.1% | +3.0% | -0.3% | — |
| Mar 12, 2026 | AMC | 0.06 | 0.04 | -29.5% | 7.81 | +2.2% | -3.2% | -0.8% | +2.0% | -8.4% | -3.0% | — |
| Nov 7, 2025 | AMC | 0.05 | 0.06 | +20.0% | 7.21 | +5.8% | +9.8% | +1.1% | +4.1% | -3.1% | -1.1% | — |
| Aug 11, 2025 | AMC | 0.03 | 0.02 | -33.3% | 7.07 | -5.5% | +6.9% | +8.6% | +0.1% | -1.0% | -3.6% | — |
| May 9, 2025 | AMC | 0.03 | 0.03 | +0.0% | 9.53 | -0.6% | +13.6% | +6.2% | -9.7% | +5.3% | +3.7% | — |
| Mar 17, 2025 | AMC | 0.04 | 0.01 | -75.0% | 12.28 | -6.4% | -30.2% | +20.0% | -0.6% | -5.0% | -5.1% | — |
| Nov 13, 2024 | AMC | — | 0.02 | — | 14.48 | -0.2% | -4.4% | -5.2% | -3.8% | +2.4% | -0.1% | — |
| Aug 13, 2024 | AMC | — | 0.01 | — | 10.40 | +3.7% | -4.0% | +7.0% | +2.0% | +8.0% | -0.3% | — |
| May 9, 2024 | AMC | — | 0.04 | — | 15.23 | +2.8% | -2.7% | +6.3% | +0.1% | -0.9% | -2.2% | — |
| Mar 26, 2024 | AMC | -0.60 | -0.68 | -13.6% | 16.79 | -3.5% | +4.4% | -0.3% | -9.3% | +7.2% | +1.0% | — |
| Oct 26, 2023 | AMC | -0.75 | -1.05 | -40.0% | 8.10 | -1.9% | -1.9% | -3.8% | -12.0% | -6.5% | +1.0% | — |
| Aug 14, 2023 | AMC | -0.07 | -0.07 | +0.0% | 5.25 | +2.9% | +5.7% | +18.9% | +9.1% | +12.5% | +0.0% | — |
| May 15, 2023 | AMC | -1.05 | 0.14 | +113.5% | 3.30 | +9.1% | +4.5% | +0.0% | +0.0% | +0.0% | +4.3% | — |
No analyst ratings available.
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| Jun 18, 2026 | Ye Weiguo | Chief Operating Officer | Sell | 3,000 | $6.35 | $19K | 700,000 | +0.00% | +2.54% |
| Jun 11, 2026 | Ye Weiguo | Chief Operating Officer | Sell | 2,800 | $6.17 | $17K | 700,000 | -0.68% | +0.00% |
| Jun 10, 2026 | Ye Weiguo | Chief Operating Officer | Sell | 5,000 | $6.24 | $31K | 700,000 | +0.00% | +2.54% |
| Jun 10, 2026 | Ye Weiguo | Chief Operating Officer | Sell | 6,418 | $6.21 | $40K | 700,000 | -2.15% | +2.80% |
| Jun 9, 2026 | Ye Weiguo | Chief Operating Officer | Sell | 3,000 | $6.15 | $18K | 700,000 | +0.00% | +2.54% |
| Jun 9, 2026 | Ye Weiguo | Chief Operating Officer | Sell | 14,500 | $6.14 | $89K | 700,000 | -2.15% | +2.80% |
| Jun 5, 2026 | Ye Weiguo | Chief Operating Officer | Sell | 15,401 | $6.40 | $99K | 700,000 | +1.32% | -1.18% |
| Jun 4, 2026 | Ye Weiguo | Chief Operating Officer | Sell | 19,575 | $6.13 | $120K | 700,000 | +1.32% | -1.18% |
| May 26, 2026 | Ye Weiguo | Chief Operating Officer | Sell | 4,000 | $6.10 | $24K | 700,000 | -3.04% | +2.34% |
| May 22, 2026 | Ye Weiguo | Chief Operating Officer | Sell | 3,500 | $6.08 | $21K | 700,000 | -3.04% | +2.34% |
| May 19, 2026 | Ye Weiguo | Chief Operating Officer | Sell | 9,120 | $6.37 | $58K | 700,000 | +2.32% | -3.04% |
| May 18, 2026 | Ye Weiguo | Chief Operating Officer | Sell | 200 | $6.62 | $1K | 700,000 | +2.32% | -3.04% |
| May 15, 2026 | Ye Weiguo | Chief Operating Officer | Sell | 13,100 | $6.65 | $87K | 700,000 | -2.79% | -1.98% |
| May 14, 2026 | Ye Weiguo | Chief Operating Officer | Sell | 15,580 | $6.91 | $108K | 700,000 | -2.79% | -1.98% |
| May 6, 2026 | Luo Ying | Chief Executive Officer | Sell | 10,136 | $8.04 | $81K | 2,565,226 | +5.66% | -3.85% |
| May 5, 2026 | Luo Ying | Chief Executive Officer | Sell | 179 | $8.01 | $1K | 2,575,362 | +5.66% | -3.85% |
8-K
Gyre Therapeutics, Inc. -- 8-K Filing
Jun 16
8-K · 7.01
! Medium
Gyre Therapeutics, Inc. -- 8-K 7.01: Regulation FD Disclosure
Jun 2
8-K · 7.01
! Medium
Gyre Therapeutics, Inc. -- 8-K 7.01: Regulation FD Disclosure
May 12
8-K · 2.02
!! High
Gyre Therapeutics, Inc. -- 8-K 2.02: Earnings Results
Gyre Therapeutics reported Q1 2026 financial results, providing investors with updates on the company's operational performance and financial condition during the period.
May 7
8-K · 2.01
!!! Very High
Gyre Therapeutics, Inc. -- 8-K 2.01: Acquisition Completed
Gyre Therapeutics completed its acquisition of Cullgen Inc., expanding its therapeutic pipeline and potentially strengthening its competitive position in the biotech market.
May 4
8-K · 1.01
!! High
Gyre Therapeutics, Inc. -- 8-K 1.01: Material Agreement
Gyre Therapeutics filed a corrected 8-K to fix a clerical error in a previously disclosed material agreement, with no substantive changes to the original filing.
Apr 17
8-K · 8.01
!! High
Unknown — 8-K 8.01: Material Event / Announcement
GYRE's forward-looking statement disclaimers suggest upcoming announcements about clinical results or strategic plans, creating uncertainty around near-term catalysts and stock direction that investors should monitor closely.
Mar 23
8-K
Unknown — 8-K Filing
Gyre's IND application for MASH liver fibrosis treatment in 2026 signals progression toward clinical development in a large market, potentially validating its therapeutic approach and supporting future revenue opportunities.
Mar 12
8-K · 7.01
! Medium
Unknown — 8-K 7.01: Regulation FD Disclosure
GYRE's lung fibrosis revenue comes primarily from rheumatoid disease patients, and management expects this profitable disease mix to persist or expand as the drug gains market adoption in the rheumatology channel.
Mar 12
8-K · 1.01
!!! Very High
Gyre Therapeutics, Inc. -- 8-K 1.01: Merger Agreement
Gyre Therapeutics agreed to merge with Cullgen Inc. in a $300 million transaction, combining the two biopharmaceutical companies.
Mar 2
Institutional (13F) — Top 19
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Vanguard Capital Management Llc | 984,204 | $7M | New | Mar 2026 |
| 2 | Northern Trust Corp | 133,841 | $933K | Added | Mar 2026 |
| 3 | Morgan Stanley | 108,996 | $770K | Added | Dec 2025 |
| 4 | Vanguard Portfolio Management Llc | 69,814 | $487K | New | Mar 2026 |
| 5 | Bank Of New York Mellon Corp | 43,144 | $301K | Added | Mar 2026 |
| 6 | Ubs Group Ag | 21,087 | $147K | Added | Mar 2026 |
| 7 | Fmr Llc | 18,717 | $130K | Added | Mar 2026 |
| 8 | Bank Of America Corp /de/ | 10,538 | $73K | Added | Mar 2026 |
| 9 | Royal Bank Of Canada | 5,605 | $39K | Reduced | Mar 2026 |
| 10 | Jpmorgan Chase & Co | 5,181 | $35K | Added | Mar 2026 |
| 11 | Wells Fargo & Company/mn | 4,290 | $30K | New | Mar 2026 |
| 12 | Bnp Paribas Financial Markets | 2,571 | $18K | Added | Mar 2026 |
| 13 | Barclays Plc | 2,300 | $16K | Reduced | Mar 2026 |
| 14 | Russell Investments Group, Ltd. | 1,124 | $8K | Reduced | Mar 2026 |
| 15 | Simplex Trading, Llc | 674 | $5K | Reduced | Mar 2026 |
| 16 | California State Teachers Retirement System | 639 | $4K | New | Mar 2026 |
| 17 | Cwm, Llc | 104 | $725 | Added | Mar 2026 |
| 18 | Smartleaf Asset Management Llc | 6 | $41 | — | Mar 2026 |
| 19 | Essential Partners Llc | 4 | $28 | New | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
Valuation
Market Cap
$634.6M
Enterprise Value
$582.1M
P/E (TTM)
-77.26x
Forward P/E
—
PEG Ratio
-2.10x
P/B
3.86x
P/S
5.42x
P/FCF
-3525.32x
EV/EBITDA
184.51x
Shares Out
103.2M
Financials (TTM)
Revenue
$117.0M
Net Income
-$6.3M
EBITDA
$3.2M
Free Cash Flow
-$180K
Op Cash Flow
$1.0M
EPS Basic
$0.06
EPS Diluted
$-0.08
EPS Forward
$-0.32
Gross Margin
95.1%
Op Margin
-0.1%
Net Margin
-5.4%
Balance Sheet
Total Assets
$166.1M
Total Liab.
$23.9M
Total Equity
$142.3M
Cash
$52.4M
LT Debt
$0
Book Value/Sh
$1.59
Debt/Equity
0.01x
Current Ratio
5.60
Quick Ratio
5.04
Returns & Growth
ROE
9.3%
ROA
5.9%
ROIC
7.7%
Rev Growth YoY
+10.2%
EPS Growth YoY
-59.8%
Price Returns
2W
+3.9%
1M
-15.8%
3M
-22.9%
6M
-21.4%
12M
-13.0%
Technicals
52W High
$8.87
52W Low
$5.56
50d MA
$6.18
200d MA
$7.28
RSI (14)
41.60
ATR (14)
$0.28
Beta
6.40
Avg Volume
94K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
Jan 13, 2023
Analyst Price Targets
Consensus
$17.00
High
$18.00
Low
$16.00
Median
$17.00
Data updated apr 25, 2026 12:50pm
· Source: financialmodelingprep.com